Scarica l'app Stockscreener
5.81
1.44%
-0.085
Dopo l'orario di chiusura:
5.81
Precedente Chiudi:
$5.895
Aprire:
$5.76
Volume 24 ore:
2.18M
Relative Volume:
0.27
Capitalizzazione di mercato:
$453.50M
Reddito:
-
Utile/perdita netta:
$-209.96M
Rapporto P/E:
-1.8386
EPS:
-3.16
Flusso di cassa netto:
$-176.27M
1 W Prestazione:
+7.99%
1M Prestazione:
+1.75%
6M Prestazione:
-51.66%
1 anno Prestazione:
-44.35%
Intervallo 1D:
$5.65
$5.87
Intervallo di 1 settimana:
$5.33
$6.1499
Portata 52W:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Nome
Replimune Group Inc
Settore
Industria
Telefono
(781) 222-9600
Indirizzo
500 UNICORN PARK, WOBURN, MA
Confronta REPL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
5.81 | 460.53M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-06-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2023-04-17 | Ripresa | Piper Sandler | Overweight |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-17 | Iniziato | BTIG Research | Buy |
| 2020-11-02 | Iniziato | Jefferies | Buy |
| 2020-10-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-09-04 | Iniziato | ROTH Capital | Buy |
| 2019-07-23 | Iniziato | Chardan Capital Markets | Buy |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-25 | Iniziato | Wedbush | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Iniziato | JP Morgan | Overweight |
| 2018-08-14 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Replimune Group Inc Borsa (REPL) Ultime notizie
Replimune's Regulatory Setback and Legal Exposure: A Cautionary Tale for Biotech Investors - AInvest
Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug ApprovalHagens Berman - PR Newswire
Replimune Group Inc. stock trend outlook and recovery pathLong Setup & Expert Approved Momentum Trade Ideas - Newser
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Levi & Korsinsky Urges Replimune Group, Inc. (REPL) Shareholders to Act Before Lead Plaintiff Deadline September 22, 2025 - ACCESS Newswire
Will Replimune Group Inc. continue its uptrendLong Setup & Real-Time Chart Breakout Alerts - Newser
Ranking Replimune Group Inc. among high performing stocks via toolsGap Up & Growth Focused Stock Reports - Newser
Real time alert setup for Replimune Group Inc. performance2025 Big Picture & Safe Capital Growth Trade Ideas - Newser
American Century Companies Inc. Grows Stake in Replimune Group, Inc. $REPL - Defense World
Developing predictive dashboards with Replimune Group Inc. dataJuly 2025 Pullbacks & Capital Efficient Trade Techniques - Newser
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - WV News
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire
Replimune’s Regulatory Crossroads: Can RP1 Navigate FDA Hurdles in Advanced Melanoma? - AInvest
Class Action Lawsuit Filed Against Replimune Group, Inc. (REPL)Recover LossesContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Can you recover from losses in Replimune Group Inc.July 2025 Breakouts & Free Community Consensus Stock Picks - Newser
Risk vs reward if holding onto Replimune Group Inc.2025 Retail Activity & Precise Swing Trade Entry Alerts - Newser
Replimune stock gains on FDA Type A meeting (REPL:NASDAQ) - Seeking Alpha
What Fibonacci levels say about Replimune Group Inc. reboundMarket Risk Report & Real-Time Buy Signal Alerts - Newser
What’s the recovery path for long term holders of Replimune Group Inc.Trade Ideas & Daily Profit Maximizing Tips - Newser
Full technical analysis of Replimune Group Inc. stockQuarterly Earnings Summary & Verified Stock Trade Ideas - Newser
What MACD signals say about Replimune Group Inc.Index Update & Consistent Growth Equity Picks - Newser
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - ACCESS Newswire
Class Action Reminder for REPL Investors: Kessler Topaz Meltzer & Check, LLP Reminds Replimune Group, Inc. (REPL) Investors of Securities Fraud Class Action Lawsuit - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL - FinancialContent
Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key DrugHagens Berman - GlobeNewswire
Levi & Korsinsky Notifies Replimune Group, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineREPL - WV News
Replimune Announces Type A Meeting Scheduled with FDA - The Manila Times
Critical FDA Meeting Scheduled: Replimune's Advanced Melanoma Treatment Faces Decisive Moment - Stock Titan
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Shareholders of Class Action Lawsuit and September 22, 2025 Deadline - ACCESS Newswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Benzinga
Detecting support and resistance levels for Replimune Group Inc.Market Activity Summary & AI Driven Stock Price Forecasts - Newser
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Replimune - GlobeNewswire
Class Action Lawsuit Filed: Replimune Group, Inc. (REPL)Join by September 22, 2025 – Contact Levi & Korsinsky - ACCESS Newswire
Can Replimune Group Inc. continue delivering strong returnsQuarterly Market Summary & Proven Capital Preservation Tips - خودرو بانک
Replimune Faces Big Swings After FDA Setback And Cash Concerns - Finimize
News impact scoring models applied to Replimune Group Inc.Portfolio Update Report & Weekly Setup with High ROI Potential - Newser
Kessler Topaz Meltzer & Check, LLP Encourages Replimune Group, Inc. Investors With Losses to Contact the Firm - NewMediaWire
Identifying reversal signals in Replimune Group Inc.July 2025 Selloffs & Verified Momentum Stock Ideas - Newser
Replimune Group Inc. Builds Base for Possible Rebound getLinesFromResByArray error: size == 0 - thegnnews.com
Bragar Eagel & Squire, P.C. Reminds Investors of Class - GlobeNewswire
How to build a dashboard for Replimune Group Inc. stockPrice Action & AI Driven Stock Movement Reports - Newser
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL | FinancialContent - FinancialContent
REPL Class Action Lawsuit Reminder: Kessler Topaz Meltzer & - GlobeNewswire
Replimune Group Inc. stock prediction for this weekMarket Growth Summary & Stock Portfolio Risk Control - Newser
REPL Class Action Reminder: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Replimune Group, Inc. Class Action Lawsuit - Morningstar
Replimune Group, Inc. (REPL) Investors: September 22, 2025 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & Check, LLP - FinancialContent
Replimune Group Inc Azioni (REPL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Replimune Group Inc Azioni (REPL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Astley-Sparke Philip | Director |
May 20 '25 |
Sale |
8.06 |
32,279 |
260,169 |
1,405,071 |
| Xynos Konstantinos | Chief Medical Officer |
May 20 '25 |
Sale |
8.06 |
7,952 |
64,093 |
146,933 |
| Schwendenman Andrew | Chief Accounting Officer |
May 20 '25 |
Sale |
8.05 |
3,287 |
26,460 |
68,284 |
| Patel Sushil | Chief Executive Officer |
May 20 '25 |
Sale |
8.06 |
25,105 |
202,346 |
343,576 |
| Hill Emily Luisa | Chief Financial Officer |
May 20 '25 |
Sale |
8.05 |
2,535 |
20,407 |
143,522 |
| Sarchi Christopher | Chief Commercial Officer |
May 20 '25 |
Sale |
8.05 |
3,749 |
30,179 |
128,296 |
| Patel Sushil | Chief Executive Officer |
Dec 16 '24 |
Sale |
12.42 |
10,000 |
124,200 |
202,014 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):